Understanding the effect of medication on the body's inflammatory response may lead to new treatments for autoimmune conditions, including psoriasis.
Plaque psoriasis is an autoimmune condition characterised by dry, itchy and scaly skin patches (plaques). It can be extremely uncomfortable to live with.
The investigational drug for this study is JNJ-77242113 and is given as an oral tablet. JNJ-77242113 proved substantial efficacy in clearing plaque psoriasis in a previous study.
The purpose of this research project is to measure how safe and effective this medication is in treating participants with plaque psoriasis. This is a three-year study, which aims to understand the medication’s inhibiting effect on the body’s inflammatory response. The outcome of this project could support new treatments to increase quality of life in people with plaque psoriasis.
Anticipated date that enrolment will close: Late 2024
Ethics
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.